# EMD Serono Research & Development trials: 87

ClinicalTrials.gov lists 87 trials with EMD Serono Research & Development Institute, Inc. as lead sponsor, 8 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by EMD Serono Research & Development Institute, Inc.: 87 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/emd-serono-research-and-development-institute-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 87
- Recruiting or not yet: 8
- Read on: November 19, 2026

## Trials

The 25 newest of 87, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 25, 2026 | NCT07840287 | A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease \[Elowen-LTE\] | EMD Serono Research & Development Institute, Inc. | Phase 3 | Recruiting | Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | 404 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840287) |
| April 24, 2026 | NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With... | EMD Serono Research & Development Institute, Inc. | Phase 3 | Recruiting | Metastatic Colorectal Cancer | 1,020 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549412) |
| January 22, 2026 | NCT07360314 | Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | EMD Serono Research & Development Institute, Inc. | Phase 1 | Recruiting | Advanced Solid Tumors | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07360314) |
| January 21, 2026 | NCT07355218 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) | EMD Serono Research & Development Institute, Inc. | Phase 3 | Recruiting | Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07355218) |
| January 12, 2026 | NCT07332481 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease | EMD Serono Research & Development Institute, Inc. | Phase 3 | Recruiting | Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07332481) |
| September 10, 2025 | NCT07166601 | M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors | EMD Serono Research & Development Institute, Inc. | Phase 1 | Recruiting | Advanced Solid Tumor | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166601) |
| July 31, 2025 | NCT07097259 | A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male... | EMD Serono Research & Development Institute, Inc. | Phase 1 | Completed | Hypogonadism | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07097259) |
| December 6, 2024 | NCT06719973 | Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) | EMD Serono Research & Development Institute, Inc. | Phase 1 | Withdrawn | Advanced Solid Tumors | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06719973) |
| November 29, 2024 | NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | EMD Serono Research & Development Institute, Inc. | Phase 1/2 | Active not recruiting | Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma... | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06710132) |
| October 15, 2024 | NCT06641908 | Anti-GD2 ADC M3554 in Advanced Solid Tumors | EMD Serono Research & Development Institute, Inc. | Phase 1 | Recruiting | Advanced Solid Tumor | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06641908) |
| July 19, 2024 | NCT06509906 | M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) | EMD Serono Research & Development Institute, Inc. | Phase 1 | Terminated | Advanced Solid Tumor | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06509906) |
| May 29, 2024 | NCT06433219 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | EMD Serono Research & Development Institute, Inc. | Phase 2 | Completed | Ovarian Cancer | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06433219) |
| May 22, 2024 | NCT06424717 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN... | EMD Serono Research & Development Institute, Inc. | Phase 2 | Withdrawn | Urothelial Carcinoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06424717) |
| May 20, 2024 | NCT06421935 | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | EMD Serono Research & Development Institute, Inc. | Phase 1 | Active not recruiting | Advanced Solid Tumor | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06421935) |
| September 28, 2023 | NCT06056310 | Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) | EMD Serono Research & Development Institute, Inc. | Phase 1 | Terminated | Head and Neck Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06056310) |
| May 31, 2023 | NCT05882734 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | EMD Serono Research & Development Institute, Inc. | Phase 1/2 | Completed | Non-Small Cell Lung Cancer | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05882734) |
| December 14, 2022 | NCT05650567 | Study of M5049 in DM and PM Participants (NEPTUNIA) | EMD Serono Research & Development Institute, Inc. | Phase 2 | Terminated | Dermatomyositis, Polymyositis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05650567) |
| July 19, 2022 | NCT05464030 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | EMD Serono Research & Development Institute, Inc. | Phase 1 | Active not recruiting | Colorectal Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05464030) |
| May 31, 2022 | NCT05396833 | Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) | EMD Serono Research & Development Institute, Inc. | Phase 1 | Completed | Metastatic or Locally Advanced Unresectable Solid Tumors | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05396833) |
| May 23, 2022 | NCT05386550 | Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | EMD Serono Research & Development Institute, Inc. | Phase 3 | Terminated | Head and Neck Cancer | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05386550) |
| May 17, 2022 | NCT05376891 | Met Non Small Cell Cancer Registry (MOMENT) | EMD Serono Research & Development Institute, Inc. | Observational | Recruiting | Cancer | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05376891) |
| April 14, 2022 | NCT05327530 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma... | EMD Serono Research & Development Institute, Inc. | Phase 2 | Active not recruiting | Locally Advanced or Metastatic Urothelial Carcinoma | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05327530) |
| January 20, 2022 | NCT05198349 | First in Human Study of M1069 in Advanced Solid Tumors | EMD Serono Research & Development Institute, Inc. | Phase 1 | Terminated | Metastatic or Locally Advanced Unresectable Solid Tumors | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05198349) |
| December 17, 2021 | NCT05162586 | The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) | EMD Serono Research & Development Institute, Inc. | Phase 2 | Completed | Systemic Lupus Erythematosus | 456 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05162586) |
| October 18, 2021 | NCT05081180 | Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors | EMD Serono Research & Development Institute, Inc. | Phase 1 | Terminated | Central Nervous System Tumors | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05081180) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 34 |
| Phase 1/2 | 5 |
| Phase 2 | 23 |
| Phase 2/3 | 1 |
| Phase 3 | 17 |
| Phase 4 | 1 |
| Observational | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 45 |
| Terminated | 25 |
| Recruiting | 8 |
| Active not recruiting | 6 |
| Withdrawn | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Neoplasms | 7 |
| Multiple Sclerosis | 7 |
| Ovarian Neoplasms | 6 |
| Neoplasm Metastasis | 6 |
| Lupus Erythematosus, Systemic | 6 |
| Multiple Sclerosis, Relapsing-Remitting | 5 |
| Breast Neoplasms | 4 |
| Colorectal Neoplasms | 4 |
| Carcinoma, Transitional Cell | 4 |
| Lupus Erythematosus, Cutaneous | 4 |
| Lupus Erythematosus, Discoid | 4 |
| Hereditary Sensory and Autonomic Neuropathies | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Urinary Bladder Neoplasms | 3 |
| Carcinoma, Renal Cell | 3 |
| Camurati-Engelmann Syndrome | 3 |
| Stomach Neoplasms | 3 |
| Central Nervous System Neoplasms | 2 |
| Arthritis, Rheumatoid | 2 |
| Head and Neck Neoplasms | 2 |
| Laryngeal Diseases | 2 |
| Uterine Cervical Neoplasms | 2 |
| Biliary Tract Neoplasms | 2 |
| Cholangiocarcinoma | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Research institutes in the United States](https://specstream.ai/data/businesses/research-institutes/united-states)
- [Hot dog restaurants in the United States](https://specstream.ai/data/businesses/hot-dog-restaurants/united-states)
- [Records storage companies in the United States](https://specstream.ai/data/businesses/records-storage-companies/united-states)
- [B2B oil and gas extraction companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-extraction-companies/united-states)
- [Footwear wholesalers in the United States](https://specstream.ai/data/businesses/footwear-wholesalers/united-states)
- [Peruvian restaurants in the United States](https://specstream.ai/data/businesses/peruvian-restaurants/united-states)
